Proteomic analysis of A2780/S ovarian cancer cell response to the cytotoxic organogold(III) compound Aubipyc

Journal of Proteomics

Volumn 103, Issue , 2014, Pages 103-120

  Gamberi, Tania ^a   Massai, Lara ^a   Magherini, Francesca ^a   Landini, Ida ^a   Fiaschi, Tania ^a   Scaletti, Federica ^a   Gabbiani, Chiara ^b   Bianchi, Laura ^c   Bini, Luca ^c   Nobili, Stefania ^a   Perrone, Gabriele ^a   Mini, Enrico ^a   Messori, Luigi ^a   Modesti, Alessandra ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c UNIVERSITY OF SIENA   (Italy)

Author keywords

Cancer; Gold compounds; Proteomics; Two dimensional electrophoresis

Indexed keywords

ANTINEOPLASTIC AGENT; AUBIPY; AURANOFIN; CISPLATIN; ORGANOGOLD COMPOUND; UNCLASSIFIED DRUG; 2,2' BIPYRIDINE; HYDROXO(6-(1,1-DIMETHYLBENZYL)-2,2'-BIPYRIDINE)GOLD(III);

AMINO ACID SEQUENCE; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BIOINFORMATICS; CANCER CELL; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG MECHANISM; FEMALE; GLUCOSE METABOLISM; GLYCOLYSIS; GOLD THERAPY; HUMAN; HUMAN CELL; IN VITRO STUDY; MASS SPECTROMETRY; MITOCHONDRION; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN METABOLISM; PROTEOMICS; PURINE SYNTHESIS; SIGNAL TRANSDUCTION; TWO DIMENSIONAL GEL ELECTROPHORESIS; UNINDEXED SEQUENCE; UPREGULATION; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; CELL PROLIFERATION; DRUG EFFECTS; METABOLISM; OVARY TUMOR; PROCEDURES; TUMOR CELL LINE;

2,2'-DIPYRIDYL; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GLYCOLYSIS; HUMANS; ORGANOGOLD COMPOUNDS; OVARIAN NEOPLASMS; PROTEOMICS;

EID: 84898827374     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2014.03.032     Document Type: Article

References (70)

1. Wang D., Lippard S.J. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005, 4:307-320.
2. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007, 7:573-584.
3. Garbutcheon-Singh K.B., Grant M.P., Harper B.W., Krause-Heuer A.M., Manohar M., Orkey N., et al. Transition metal based anticancer drugs. Curr Top Med Chem 2011, 11:521-542.
4. Tiekink E.R.T. Gold derivatives for the treatment of cancer. Crit Rev Oncol Hematol 2002, 42:225-248.
5. Messori L., Marcon G., Orioli P., Fontani M., Zanello P., Bergamo A., et al. Molecular structure, solution chemistry and biological properties of the novel [ImH] [trans -lrCl(4)(Im)(DMSO)], (I) and of the orange form of [(DMSO)(2)H][trans-IrCl4 (DMSO)(2)], (II), complexes. J Inorg Biochem 2003, 95:37-46.
6. Nobili S., Mini E., landini I., Gabbiani C., Casini A., Messori L. Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies. Med Res Rev 2010, 30:550-580.
7. Sun R.W.Y., Che C.M. The anti-cancer properties of gold(III) compounds with dianionic porphyrin and tetradentate ligands. Coord Chem Rev 2009, 253:1682-1691.
8. Gabbiani C., Casini A., Messori L. Gold(III) compounds as anticancer drugs. Gold Bull 2007, 40:73-81.
9. Messori L., Abbate F., Marcon G., Orioli P., Fontani M., Mini E., et al. Gold(III) complexes as potential antitumor agents: solution chemistry and cytotoxic properties of some selected gold(III) compounds. J Med Chem 2000, 43:3541-3548.
10. Ronconi L., Giovagnini L., Marzano C., Bettio F., Graziani R., Pillon G., et al. Gold dithiocarbamate derivatives as potential antineoplastic agents: design, spectroscopic properties, and in vitro antitumor activity. Inorg Chem 2005, 44:1867-1881.
11. Che C.M., Sun R.W.Y., Yu W.Y., Ko C.B., Zhu N.Y., Sun H.Z. Gold(III) porphyrins as a new class of anticancer drugs: cytotoxicity, DNA binding and induction of apoptosis in human cervix epitheloid cancer cells. Chem Commun 2003, 1718-1719.
12. Coronnello M., Mini E., Caciagli B., Cinellu M.A., Bindoli A., Gabbiani C., et al. Mechanisms of cytotoxicity of selected organogold(III) compounds. J Med Chem 2005, 48:6761-6765.
13. Messori L., Marcon G., Cinellu M.A., Coronnello M., Mini E., Gabbiani C., et al. Solution chemistry and cytotoxic properties of novel organogold(III) compounds. Bioorg Med Chem 2004, 12:6039-6043.
14. Gabbiani C., Casini A., Messori L., Guerri A., Cinellu M.A., Mighetti G., et al. Structural characterization, solution studies, and DFT calculations on a series of binuclear gold(III) oxo complexes: relationships to biological properties. Inorg Chem 2008, 47:2368-2379.
15. Shaw C.F., Cohen M.I., Barnhardt R. Inspiratory-modulated neurons of the rostrolateral pons - effects of pulmonary afferent input. Brain Res 1989, 485:179-184.
16. Messori L., Orioli P., Tempi C., Marcon G. Interactions of selected gold(III) complexes with calf thymus DNA. Biochem Biophys Res Commun 2001, 281:352-360.
17. Barnard P.J., Berners-Price S.J. Targeting the mitochondrial cell death pathway with gold compounds. Coord Chem Rev 2007, 251:1889-1902.
18. Rigobello M.P., Scutari G., Boscolo R., Bindoli A. Induction of mitochondrial permeability transition by auranofin, a gold(I)-phosphine derivative. Br J Pharmacol 2002, 136:1162-1168.
19. Bindoli A., Rigobello M.P., Scutari G., Gabbiani C., Casini A., Messori L. Thioredoxin reductase: a target for gold compounds acting as potential anticancer drugs. Coord Chem Rev 2009, 253:1692-1707.
20. Jeon K.I., Byun M.S., Jue D.M. Gold compound auranofin inhibits I kappa B kinase (IKK) by modifying Cys-179 of IKK beta subunit. Exp Mol Med 2003, 35:61-66.
21. Marcon G., Carotti S., Coranello M., Messori L., Mini E., Orioli P., et al. Gold(III) complexes with bipyridyl ligands: solution chemistry, cytotoxicity, and DNA binding properties. J Med Chem 2002, 45:1672-1677.
22. Gabbiani C., Cinellu M.A., Maiore L., Massai L., Scaletti F., Messori L. Chemistry and biology of three representative gold(III) compounds as prospective anticancer agents. Inorg Chim Acta 2012, 393:115-124.
23. Rigobello M.P., Messori L., Marcon G., Cinellu M.A., Bragadin M., Folga A., et al. Gold complexes inhibit mitochondrial thioredoxin reductase: consequences on mitochondrial functions. J Inorg Biochem 2004, 98:1634-1641.
24. Wang Y., Chiu J.-F. Proteomic approaches in understanding action mechanisms of metal-based anticancer drugs. Metal-Based Drugs 2008, 716329.
25. Yim E.K., Lee K.H., Kim C.J., Park J.S. Analysis of differential protein expression by cisplatin treatment in cervical carcinoma cells. Int J Gynecol Cancer 2006, 16:690-697.
26. Yao Y., Jia X.Y., Tian H.Y., Jiang Y.X., Xu G.J., Qian Q.J., et al. Comparative proteomic analysis of colon cancer cells in response to oxaliplatin treatment. Biochim Biophys Acta 2009, 1794:1433-1440.
27. Wang Y., He Q.Y., Che C.M., Chiu J.F. Proteomic characterization of the cytotoxic mechanism of gold (III) porphyrin 1a, a potential anticancer drug. Proteomics 2006, 6:131-142.
28. Magherini F., Modesti A., Bini L., Puglia M., Landini I., Nobili S., et al. Exploring the biochemical mechanisms of cytotoxic gold compounds: a proteomic study. J Biol Inorg Chem 2010, 15:573-582.
29. Guidi F., Landini I., Puglia M., Magherini F., Gabbiani C., Cinellu M.A., et al. Proteomic analysis of ovarian cancer cell responses to cytotoxic gold compounds. Metallomics 2012, 4:307-314.
30. Guidi F., Puglia M., Gabbiani C., Landini I., Gamberi T., Fregona D., et al. 2D-DIGE analysis of ovarian cancer cell responses to cytotoxic gold compounds. Mol Biosyst 2012, 8:985-993.
31. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990, 82:1107-1112.
32. Wessel D., Flugge A. A method for the quantitative recovery of protein in dilute solution in the presence of detergents and lipids. Anal Biochem 1984, 138:141-143.
33. Hochstrasser D.F., Harrington M.G., Hochstrasser A.C., Miller M.J., Merril C.R. Methods for increasing the resolution of two-dimensional protein electrophoresis. Anal Biochem 1988, 173:424-435.
34. Candiano G., Bruschi M., Musante L., Santucci L., Ghiggeri G.M., Carnemolla B., et al. Blue silver: a very sensitive colloidal Coomassie G-250 staining for proteome analysis. Electrophoresis 2004, 25:1327-1333.
35. Karp N.A., Spencer M., Lindsay H., O'Dell K., Lilley K.S. Impact of replicate types on proteomic expression analysis. J Proteome Res 2005, 4:1867-1871.
36. Hunt S.M., Thomas M.R., Sebastian L.T., Pedersen S.K., Harcourt R.L., Sloane A.J., Wilkins M.R. Optimal replication and the importance of experimental design for gel-based quantitative proteomics. Proteome Res 2005, 4:809-819.
37. Antonov A.V. BioProfiling.de: analytical web portal for high-throughput cell biology. Nucleic Acids Res 2011, 39:W323-W327.
38. Antonov A.V., Dietmann S., Rodchenkov I., Mewes H.W. PPI spider: a tool for the interpretation of proteomics data in the context of protein-protein interaction networks. Proteomics 2009, 9:2740-2749.
39. Masoudi-Nejad A., Ansariola M., Kashani Z.R., Salehzadeh-Yazdi A., Khakabimamaghani S. CytoKavosh: a cytoscape plug-in for finding network motifs in large biological networks. PLoS One 2012, 7:e43287.
40. Casini A., Kelter G., Gabbiani C., Cinellu M.A., Minghetti G., Fregona D., et al. Chemistry, antiproliferative properties, tumor selectivity, and molecular mechanisms of novel gold(III) compounds for cancer treatment: a systematic study. J Biol Inorg Chem 2009, 14:1139-1149.
41. Storey J.D., Tibshirani R. Statistical significance for genome wide studies. Proc Natl Acad Sci U S A 2003, 100:9440-9445.
42. Karp N.A., Lilley K.S. Design and analysis issues in quantitative proteomics studies. Proteomics 2007, 1:42-50.
43. Di Michele M., Della Corte A., Cicchillitti L., Del Boccio P., Urbani A., Ferlini C., et al. A proteomic approach to paclitaxel chemoresistance in ovarian cancer cell lines. Biochim Biophys Acta 2009, 1794:225-236.
44. Sun W., Xing B., Sun Y., Du X., Lu M., Hao C., et al. Proteome analysis of hepatocellular carcinoma by two-dimensional difference gel electrophoresis. Mol Cell Proteomics 2007, 6:1798-1808.
45. Huang D.W., Sherman B.T., Lempicki R.A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009, 4:44-57.
46. Huang D.W., Sherman B.T., Lempicki R.A. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 2009, 37:1-13.
47. Dekker C., Stirling P.C., McCormack E.A., Filmore H., Paul A., Brost R.L., et al. The interaction network of the chaperonin CCT. EMBO J 2008, 27:1827-1839.
48. Ott I. On the medicinal chemistry of gold complexes as anticancer drugs. Coord Chem Rev 2009, 253:1670-1681.
49. Messori L., Scaletti F., Massai L., Cinellu M.A., Gabbiani C., Vergarad A., et al. The mode of action of anticancer gold-based drugs: a structural perspective. Chem Commun 2013, 49:10100-10102.
50. Gamberi T., Magherini F., Bini L., Messori L., Gabbiani C., Pietrovito L., et al. New insights into the molecular mechanisms of selected anticancer compounds through bioinformatic analysis of proteomic data. J Proteomics Bioinform 2013, S6-006.
51. 2+ homeostasis. PLoS One 2011, 6:e19290.
52. Kundu J., Wahab S.M., Kundu J.K., Choi Y.L., Erkin O.C., Lee H.S., et al. Tob1 induces apoptosis and inhibits proliferation, migration and invasion of gastric cancer cells by activating Smad4 and inhibiting β-catenin signaling. Int J Oncol 2012, 41:839-848.
53. Braig S., Bosserhoff A.K. Death inducer-obliterator 1 (Dido1) is a BMP target gene and promotes BMP-induced melanoma progression. Oncogene 2013, 32:837-848.
54. Choudhary S., Kalita M., Fang L., Patel K.V., Tian B., Zhao Y., et al. Inducible tumor necrosis factor (TNF) receptor-associated factor-1 expression couples the canonical to the non-canonical NF-κB pathway in TNF stimulation. J Biol Chem 2013, 288:14612-14623.
55. Merkwirth C., Martinelli P., Korwitz A., Morbin M., Brönneke H.S., Jordan S.D., et al. Loss of prohibitin membrane scaffolds impairs mitochondrial architecture and leads to tau hyperphosphorylation and neurodegeneration. PLoS Genet 2012, 8:e1003021.
56. Bettayeb K., Oumata N., Zhang Y., Luo W., Bustos V., Galons H., et al. Small-molecule inducers of Aβ-42 peptide production share a common mechanism of action. FASEB J 2012, 26:5115-5123.
57. Tiligada E. Chemotherapy: induction of stress responses. Endocr Relat Cancer 2006, 13:S115-S124.
58. Herr I., Debatin K.M. Cellular stress response and apoptosis in cancer therapy. Blood 2001, 98:2603-2614.
59. Kohno K., Uchiumi T., Niina I., Wakasugi T., Igarashi T., Momii Y., et al. Transcription factors and drug resistance. Eur J Cancer 2005, 41:2577-2586.
60. Calderwood S.K., Khaleque M.A., Sawyer D.B., Ciocca D.R. Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci 2006, 31:164-172.
61. Castagna A., Antonioli P., Astner H., Hamdan M., Righetti S.C., Perego P., et al. A proteomic approach to cisplatin resistance in the cervix squamous cell carcinoma cell line A431. Proteomics 2004, 4:3246-3267.
62. Altenberg B., Greulich K.O. Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. Genomics 2004, 84:1014-1020.
63. Mori-Iwamoto S., Kuramitsu Y., Ryozawa S., Mikuria K., Fujimoto M., Maehara S., et al. Proteomics finding heat shock protein 27 as a biomarker for resistance of pancreatic cancer cells to gemcitabine. Int J Oncol 2007, 31:1345-1350.
64. Suh D.H., Kim M.-K., No J.H., Chung H.H., Song Y.S. Metabolic approaches to overcoming chemoresistance in ovarian cancer. Ann N Y Acad Sci 2011, 1229:53-60.
65. Yan X.D., Pan L.Y., Yuan Y., Lang J.H., Mao N. Identification of platinum-resistance associated proteins through proteomic analysis of human ovarian cancer cells and their platinum-resistant sublines. J Proteome Res 2007, 6:772-780.
66. Smith L., Welham K.J., Watson M.B., Drew P.J., Lind M.J., Cawkwell L. The proteomic analysis of cisplatin resistance in breast cancer cells. Oncol Res 2007, 16:497-506.
67. Marlin J.W., Chang Y.-W.E., Jakobi R. Caspase activation of p21-Activated kinase 2 occurs during cisplatin-induced apoptosis of SH-SY5Y neuroblastoma cells and in SH-SY5Y cell culture models of Alzheimer's and Parkinson's disease. Journal of Cell Death 2010, 3:23-32.
68. Liang X.J., Finkel T., Shen D.W., Yin J.J., Aszalos A., Gottesman M.M. SIRT1 contributes in part to cisplatin resistance in cancer cells by altering mitochondrial metabolism. Mol Cancer Res 2008, 6:1499-1506.
69. Ahn B.H., Kim H.S., Song S., Lee I.H., Liu J., Vassilopoulos A., et al. A role for the mitochondrial deacetylase Sirt3 in regulating energy homeostasis. Proc Natl Acad Sci U S A 2008, 105:14447-14452.
70. Mohammad R.M., Banerjee S., Li Y., Aboukameel A., Kucuk O., Sarkar F.H. Cisplatin-induced antitumor activity is potentiated by the soy isoflavone genistein in BxPC-3 pancreatic tumor xenografts. Cancer 2006, 106:1260-1268.